Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology · Published 2026-07-28 · DOI 10.1002/bcp.70721

Free full text

Authors (3)

Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kiguba, R., Ssesanga, M., Pirmohamed, M. (2026). Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70721

Related articles

• Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis · Pharmacogenetics and Genomics · 2025 · Cites or is cited by this article
• Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens · Pharmacogenetics and Genomics · 2023 · Cites or is cited by this article
• Relationships among nitrous oxide exposure, neurological injury and biomarkers · British Journal of Clinical Pharmacology · 2026 · Same journal
• Predicting cognitive function in Alzheimer's clinical trials via amyloid β‐protein biomarkers · British Journal of Clinical Pharmacology · 2026 · Same journal
• Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort study · British Journal of Clinical Pharmacology · 2026 · Same journal
• MT‐RNR1 genotype testing for preventing aminoglycoside‐mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx) · British Journal of Clinical Pharmacology · 2026 · Same journal
• Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus · British Journal of Clinical Pharmacology · 2026 · Same journal
• Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025 · British Journal of Clinical Pharmacology · 2026 · Same journal
• Analysis of spontaneous reports of suspected adverse reactions related to medical cannabis from the Italian Phytovigilance System · British Journal of Clinical Pharmacology · 2026 · Same journal
• A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience · British Journal of Clinical Pharmacology · 2026 · Same journal